We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Proceeds to advance three late-stage programs towards registration, prepare for commercialization and progress the company’s gene therapy platform Boston, USA and London, UK, August 13, 2018 / B3C newswire